HMGB1 and dysplasia: There was an increased intensity of nuclear HMGB1 in the background BO in those that had progressed to either dysplasia (71%) or cancer (67%) compared with BO from non-progressors (27%), p ≤ 0.017 and p = 0.024, respectively (Supplementary Table 3).